Somatostatin analogue - Italfarmaco

Drug Profile

Somatostatin analogue - Italfarmaco

Alternative Names: ITF-2984; ITF2984 diacetate

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Italfarmaco
  • Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Corticotropin-releasing factor antagonists; Growth hormone releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Italy (SC, Injection)
  • 01 Feb 2016 Italfarmaco completes a phase II trial for Acromegaly in Czech Republic, France, Hungary, Italy, Netherlands, Poland, Romania, Serbia and Spain (NCT02111044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top